Intended for healthcare professionals


UK drug companies must disclose funding of patients' groups

BMJ 2006; 332 doi: (Published 12 January 2006) Cite this as: BMJ 2006;332:69

A welcome initiative but...

This is a welcome initiative but probably defective.

For practical purposes it is essential not so much that the drug
companies themselves publish the information as that the sponsored
organisations publish it: otherwise you are still left trying to guess
which drug companies are sponsoring them, if any.

I also have no doubt that the companies themselves will maintain that
they are in some way in technical compliance with this recommendation, but
a scoot round the websites of several high profile pharmaceutical
companies is presently not very revealing.

It might become helpful if an easily accessible central register was
set up, as a point of reference.

Competing interests:
Autistic son

Competing interests: No competing interests

16 January 2006
John Stone
London N22